MRD Testing Is Becoming the Most Important Tool in Oncology Drug Development: Q&A with Eric Matthews
MRD testing is transforming oncology trials — compressing timelines, enriching populations, and generating earlier answers.
Feature|Articles|September 14, 2026
Why Fragmented Contract Processes Are Slowing Pharmaceutical Operations
Author(s)Tom Cowen
Pharma has digitized nearly everything — but contract management remains fragmented, creating compliance risk and slowing execution across the enterprise.
Advertisement
Advertisement
The pharmaceutical industry has made significant investments in digital transformation, ranging from AI-led drug discovery and clinical trial optimization to advanced analytics and real-world evidence generation. As a result, digital technologies are changing how the industry discovers, commercializes and delivers medicines.
Related to this article
Compounding pharmacies that set their own safety and accreditation standards now stand the best chance of keeping patient access intact before heavier regulation does it for them.
Two FDA approvals, six platform deals, a European alarm, a Novo listing debate, and a China mega-deal — this week's biggest pharma stories, explained.
FDA has approved Welireg plus Lenvima for previously treated advanced clear cell renal cell carcinoma.
FDA approves Onswik, Eli Lilly's once-weekly basal insulin for adults with type 2 diabetes.
Why self-reported data fails clinical trials — and how RWD and AI fix enrollment accuracy before the first patient is dosed.
Foghorn Therapeutics and Eli Lilly are discontinuing their SMARCA2 degrader Fhd-909 after Phase I data fell short on efficacy.
Novartis licenses Abogen's mRNA-encoded CD19xCD3 T-cell engager, while AstraZeneca and Daiichi Sankyo partner with Summit Therapeutics.
Advertisement
Advertisement